君实生物 · Junshi Biosciences
← News archive

· Regulatory update

China accepts application for subcutaneous toripalimab in urothelial carcinoma

China’s National Medical Products Administration accepted for review a supplemental application for subcutaneous toripalimab in combination with disitamab vedotin.

The application concerns first-line treatment for patients with locally advanced or metastatic HER2-expressing urothelial carcinoma.

Read the full company release